How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/disseminated-gonococcal-infection.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Disseminated Gonococcal Infection — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Disseminated Gonococcal Infection (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Disseminated Gonococcal Infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Vibramycin	doxycycline	Generic (originally Pfizer)	Tetracycline antibiotic	72 kDa type IV collagenase, Stromelysin-1, Collagenase 3	1967-01-01
Penicillin G Potassium In Plastic Container	Benzylpenicillin	Pfizer	Penicillin-class Antibacterial		1947-01-01
penicillin	penicillin	Karlstad University		Bacterial penicillin-binding protein, Beta-lactamase, Beta-lactamase TEM
Ceftriaxon	Ceftriaxon	Centre Hospitalier Universitaire Vaudois		Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A
SPECT	SPECT	Tomsk National Research Medical Center of the Russian Academy of Sciences		30S ribosomal protein S12
Doxycyclin	Doxycyclin	Bulovka Hospital		72 kDa type IV collagenase, Stromelysin-1, Collagenase 3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Disseminated Gonococcal Infection
Bulovka Hospital · 1 drug in Disseminated Gonococcal Infection
Centre Hospitalier Universitaire Vaudois · 1 drug in Disseminated Gonococcal Infection
GSK · 1 drug in Disseminated Gonococcal Infection
Generic (originally Pfizer) · 1 drug in Disseminated Gonococcal Infection
Generic (originally Roche) · 1 drug in Disseminated Gonococcal Infection
Karlstad University · 1 drug in Disseminated Gonococcal Infection
Pfizer · 1 drug in Disseminated Gonococcal Infection
Tomsk National Research Medical Center of the Russian Academy of Sciences · 1 drug in Disseminated Gonococcal Infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Disseminated Gonococcal Infection:

Cite this brief

Drug Landscape (2026). Disseminated Gonococcal Infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/disseminated-gonococcal-infection. Accessed 2026-06-10.

Disseminated Gonococcal Infection full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing